KALEIDO BIOSCIENCES, INC.

(KLDO)
  Report
Delayed OTC Markets  -  05/27 03:59:47 pm EDT
0.0535 USD   -10.54%
04/20KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from S&P Global BMI Index
CI
04/20KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from S&P TMI Index
CI
04/15KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from NASDAQ Composite Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

KALEIDO BIOSCIENCES, INC. : Other Events (form 8-K)

01/28/2022 | 04:46pm EDT

Item 8.01 Other Events.

The Company has decided to halt work on a planned Phase 2 chronic obstructive pulmonary disease (COPD) study and terminate its agreement with the COPD Foundation. These decisions were made in order to re-align resources and focus the Company's efforts.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about KALEIDO BIOSCIENCES, INC.
04/20KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from S&P Global BMI Index
CI
04/20KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from S&P TMI Index
CI
04/15KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from NASDAQ Composite Index
CI
04/14Top Premarket Gainers
MT
04/14CAPITALGAINSREPORT : Must See Healthcare Stocks Under $1 (WHSI, KLDO, AGRX, PTE, AKBA)
AQ
04/13Top Premarket Gainers
MT
04/08Top Midday Decliners
MT
04/08Kaleido Biosciences Ceases Operations, Will Delist From Nasdaq; Shares Fall
MT
04/08KALEIDO BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing ..
AQ
04/08Kaleido Biosciences, Inc. Announces Management Changes
CI
More news
Analyst Recommendations on KALEIDO BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 2,28 M 2,28 M -
EV / Sales -1
EV / Sales 0
Nbr of Employees 76
Free-Float 95,0%
Chart KALEIDO BIOSCIENCES, INC.
Duration : Period :
Kaleido Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KALEIDO BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 0,05
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Theo Melas-Kyriazi Chairman
Kimberly Hocknell Senior Vice President-Technical Operations
Alison Long Chief Medical Officer
Mark Wingertzahn Head-Development, SVP-Research & Development
Bonnie L. Bassler Independent Director
Sector and Competitors
1st jan.Capi. (M$)
KALEIDO BIOSCIENCES, INC.-97.50%3
MODERNA, INC.-46.53%54 016
LONZA GROUP AG-28.07%42 292
IQVIA HOLDINGS INC.-26.37%39 319
SEAGEN INC.-10.44%25 487
ICON PUBLIC LIMITED COMPANY-29.73%17 693